相关实验视频

Updated: Jan 9, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

微生物组和CAR T细胞治疗结果的代谢物生物标志物在复发性/耐药性扩散性大B细胞淋巴瘤中的结果

Sang Eun Yoon¹, Woorim Kang², Junhun Cho¹

¹Samsung Medical Center, SEOUL, Korea, Republic of.

|December 9, 2025

概括

肠道微生物组可以预测CAR T细胞治疗在扩散大B细胞淋巴瘤中的成功. 特定的细菌,如 Bacteroides fragilis 和 inosine 代谢,显示出作为治疗结果和毒性生物标志物的潜力.

科学领域:

在瘤学瘤学.
微生物组研究微生物组研究
免疫治疗是一种免疫疗法.

背景情况:

CD19 CAR T细胞疗法为复发性/耐药性扩散性大B细胞淋巴瘤 (RR-DLBCL) 提供了突破性进展.
治疗的挑战包括治疗失败和与免疫相关的不良事件 (AE).
肠道微生物组作为CAR T细胞治疗的预测生物标志物的作用正在调查中.

研究的目的:

研究肠道微生物组作为CAR T细胞治疗结果和RR-DLBCL患者毒性的预测生物标志物的潜力.
识别与治疗反应和AE相关的特定微生物特征和代谢途径.

主要方法:

全基因组测序元基因组学被用来分析RR-DLBCL患者和对照者的便和血清样本.
样品是在射和输液后一个月收集的.
分析包括对应者,非响应者,健康对照者和新诊断的DLBCL患者之间的比较.

主要成果:

与对照组相比,RR-DLBCL患者表现出肠道失调.
响应者显示出更高的 Bacteroides fragilis,而非响应者则显示出更高的 Faecalibacterium prausnitzii.
在响应者中观察到丰富的氨酸生物合成途径和高血清氨酸,与无进展生存相关.
不同的微生物种群和血清脂肪酸与CAR T细胞相关的AE有关.

结论:

肠道微生物组特征,包括 Bacteroides fragilis 和 inosine 代谢,可以作为 CAR T 细胞治疗结果和 RR-DLBCL 中毒性的候选生物标志物.
显著的微生物和代谢特征与治疗反应和不良事件有关.
需要进行更大的前性研究来验证这些探索性发现,并评估基于微生物组的优化策略.

更多相关视频

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.